Document Detail


Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients.
MedLine Citation:
PMID:  16863483     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
STUDY OBJECTIVE: To identify the factors affecting tacrolimus apparent total body clearance (Cl/F [F = bioavailability]) in adult liver transplant recipients. DESIGN: Population pharmacokinetic analysis using data from a retrospective chart review. SETTING: University-affiliated hospital in Seoul, South Korea. PATIENTS: Fifty-one adult liver transplant recipients who had received tacrolimus after transplantation. MEASUREMENTS AND MAIN RESULTS: Data on 35 adult liver transplant recipients for model building and 16 patients for model validation were obtained retrospectively. Population average parameter estimates of Cl/F and apparent volume of distribution (V/F) were sought by using the nonlinear mixed-effect model (NONMEM) program. A number of clinical covariates were screened for their influence on these pharmacokinetic parameters. The final optimal population model related Cl/F to total bilirubin, early (< or = 3 days) and late (> 35 days) postoperative days, international normalized ratio (INR), and graft:recipient weight ratio (GRWR). The NONMEM estimates indicated that the Cl/F of tacrolimus was decreased in patients with a small graft, hyperbilirubinemia, and a high INR. In addition, the Cl/F of tacrolimus almost doubled 4 days after transplantation, but decreased with an increase in duration of therapy after day 35. Mean prediction error and mean absolute prediction error were 0.26 and 3.78 ng/ml, respectively, for the validation sample. A final analysis in all 51 patients, which consisted of 1775 blood samples for concentration measurements, identified the following regression model: Cl/F (L/hr) = (0.36 + 2.01/POD * L) * TBIL(-0.23 (TBIL = 1 if TBIL level < or = 1.2 mg/dl, otherwise TBIL = TBIL level)) *49((if POD < or = 3 days)) * 0.75((if INR > 1.4)) * 0.86((if GRWR < or = 1.25%)) * WT, where L was 1 if postoperative day (POD) was greater than 35 days, otherwise L was 0; V/F was 568 L, TBIL was total bilirubin, and WT was body weight. The interindividual variabilities (coefficients of variation) in Cl/F and V/F were 35.35% and 68.12%, respectively. The residual variability was 3.14 ng/ml. CONCLUSION: These findings could be useful to the health care provider for adjustment of tacrolimus dosage in adult liver transplant recipients with various clinical factors.
Authors:
Ju Yeun Lee; Hyeon Joo Hahn; In Ja Son; Kyung Suk Suh; Nam Joon Yi; Jung Mi Oh; Wan Gyoon Shin
Related Documents :
15665753 - Effects of hematocrit value on microparticle enzyme immunoassay of tacrolimus concentra...
15302193 - Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal tr...
10199733 - Reversal of naturally occuring diabetes in primates by unmodified islet xenografts with...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacotherapy     Volume:  26     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-07-25     Completed Date:  2006-12-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1069-77     Citation Subset:  IM    
Affiliation:
Department of Pharmacy, Seoul National University Hospital, Jongno-gu, Seoul, South Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Asian Continental Ancestry Group
Bilirubin / blood
Biological Availability
Body Weight
Female
Humans
Immunosuppressive Agents / blood,  pharmacokinetics*
International Normalized Ratio
Liver / metabolism*
Liver Transplantation*
Male
Medical Records
Metabolic Clearance Rate
Middle Aged
Models, Biological
Organ Size
Regression Analysis
Reproducibility of Results
Retrospective Studies
Tacrolimus / blood,  pharmacokinetics*
Time Factors
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 109581-93-3/Tacrolimus; 635-65-4/Bilirubin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Next Document:  Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.